• Necrosulfonamide: Mapping Necroptosis to Translation

  2026-09-13

  Necrosulfonamide provides a pathway-positioned way to test whether MLKL membrane execution links upstream stress biology to translational injury. This article interprets recent cardiac microvascular ischemia–reperfusion findings and offers a practical framework for using NSA in mechanistic, cancer, and exploratory neurodegenerative disease models.

• COX-2, Ischemia, and Muscle Revascularization

  2026-09-12

  This study shows that COX-2 has a time-dependent role after Bothrops asper venom injury: it protects muscle microvessels during acute ischemia, yet its early inhibition later enhances proangiogenic and matrix-remodeling signals. The findings refine how selective COX-2 inhibition should be interpreted in muscle injury and revascularization models.

• Leptin (116-130), amide, mouse Workflows

  2026-09-11

  Use this defined leptin fragment to build controlled assays for energy balance, obesity, diabetes, and immunometabolic signaling. Practical preparation guidance, comparative assay design, and a cautious SIRT6–AMPK–NLRP3 extension help distinguish direct peptide effects from context-dependent leptin resistance.

• A-1210477: Mapping MCL-1-Dependent Apoptosis

  2026-09-11

  A-1210477 is a selective MCL-1 inhibitor for distinguishing target engagement from genuine apoptotic dependence. This article develops an evidence-driven framework for mitochondrial apoptosis assay design, mechanistic validation, combination studies, and translational interpretation.

• FGFR2 Fusion ICC: HDO and Asparagine Depletion

  2026-09-10

  The reference study develops a cholesterol-conjugated DNA/RNA heteroduplex oligonucleotide that selectively suppresses the FGFR2-AHCYL1 fusion in intrahepatic cholangiocarcinoma. It also identifies an EGFR–STAT1–ASNS adaptation pathway and shows why asparagine depletion may improve responses to fusion-directed treatment in preclinical models.

• HyperScript First-Strand cDNA Synthesis Kit Workflow

  2026-09-10

  Translate scarce, long, or structurally difficult RNA into dependable templates for PCR amplification and qPCR reaction workflows. The kit combines primer flexibility with a thermally stable, high-affinity reverse transcriptase for applications such as EV-associated lncRNA profiling and low copy gene reverse transcription.

• Imidazoline Antagonists and β-Cell K+ Channels

  2026-09-09

  The 1992 study showed that alinidine, antazoline, phentolamine, and tolazoline enhance insulin release primarily by inhibiting ATP-sensitive K+ channels in pancreatic β-cells, rather than solely by blocking α2-adrenoceptors. Its combination of 86Rb efflux, patch-clamp, and insulin-secretion experiments provides a useful framework for separating receptor-dependent effects from direct ion-channel pharmacology.

• PD-L1–IL-6 Crosstalk in Primary Sclerosing Cholangitis

  2026-09-09

  The reference study combines spatial proteomics with cell-cell cross-talk analysis to examine how immune checkpoint and cytokine signaling are organized in human primary sclerosing cholangitis. Its central contribution is the identification of a PD-L1–IL-6 interaction at the epithelial-immune interface, providing a spatially informed framework for studying persistent inflammation in the biliary tree.

• Acetoacetic Acid Sodium Salt in Translational Research

  2026-09-08

  A translational framework for using Acetoacetic acid sodium salt to study ketone-body biology, energy metabolism research, diabetes metabolic imbalance, and assay reproducibility—while borrowing analytical discipline from isotope-labeled drug development.

• AARS2 Lactylation of ULK1 in Clear Cell Renal Cancer

  2026-09-08

  The reference study identifies AARS2-mediated lactylation of ULK1 at lysine 46 as a metabolic control point for autophagy initiation in clear cell renal cell carcinoma. This modification enhances ULK1 signaling through ATG14 and supports tumor metastasis, while a cell-penetrating peptide targeting the modified site showed therapeutic potential in cellular and animal models.

• SB203580: p38 MAPK Mechanism and Use

  2026-09-07

  SB203580 is an ATP-competitive p38 MAPK inhibitor used to dissect inflammation, stress signaling, neuroprotection studies, and multidrug resistance reversal. Its reported biochemical potency and formulation limits support controlled pathway experiments, but its off-target activity at higher concentrations requires orthogonal validation.

• Imidazoline Antagonists and β-Cell K+ Channels

  2026-09-07

  The 1992 study showed that several imidazoline α2-adrenoceptor antagonists increase insulin release primarily by inhibiting ATP-sensitive K+ channels rather than by blocking α2-adrenoceptors. Its combination of 86Rb efflux, whole-cell patch-clamp, and insulin-secretion experiments provides a useful framework for separating receptor-mediated effects from direct ion-channel pharmacology.

• HyperScript™ Reverse Transcriptase Workflows

  2026-09-05

  HyperScript™ Reverse Transcriptase supports demanding RNA-to-cDNA workflows involving structured transcripts, scarce RNA, and long targets. This practical guide translates a laying-hen transcriptomics study into assay decisions for cDNA synthesis for qPCR, validation experiments, and troubleshooting.

• Glycogen Colorimetric Assay Kit II in Exercise Studies

  2026-09-04

  The Glycogen Colorimetric Assay Kit II converts tissue glycogen into a 450 nm signal and is designed for matrices that can challenge oxidase-based assays. This workflow pairs time-matched liver and muscle sampling with circadian exercise studies, enabling high-throughput comparisons without treating glycogen as the sole explanation for performance adaptation.

• 4-Hydroxytamoxifen Protocol and QC Guide

  2026-09-04

  This guide provides practical handling and quality-control guidance for 4-Hydroxytamoxifen (SKU B6167) in DMSO-based estrogen receptor, cancer, apoptosis, and cardiac myocyte workflows. It is not appropriate for protocols requiring water- or ethanol-based solubilization, and the supplied dossier does not establish a universal dose, exposure time, or endpoint.

8671 records 1/579 page Next 12345 下5页 Last page